Other studies also underscore that anti-ROR1 mAb treatment enhanced venetoclax activity in CLL and MCL [125], suggesting that, in ROR1-positive hematological cancers, this approach represents a promising strategy. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.